USP <61> and <62>: The Microbial Testing Chapters Supplement Brands Most Often Get Wrong

There’s a gap that shows up in supplement manufacturing more often than it should. A brand submits their finished product to a lab, gets back a certificate of analysis showing the total aerobic count and yeast-and-mold results are within spec, and files it away satisfied. Then an FDA investigator walks in for a routine cGMP inspection and asks to see the specified organism results. Silence.

USP <61> and <62> are two different chapters covering two fundamentally different things. Running one without the other is one of the most consistent compliance gaps we see across brands of every size — from single-SKU startups to established contract manufacturers with decades in the industry.

What USP <61> and <62> Actually Cover

Most people in the supplement industry have heard these chapter numbers mentioned together so often that they’ve blurred into one. They’re related but distinct.

USP <61> — Microbiological Examination of Nonsterile Products: Microbial Enumeration Tests — covers the methods for counting microorganisms. It provides validated procedures for determining the Total Aerobic Microbial Count (TAMC) and Total Combined Yeast and Mold Count (TYMC) in a sample. These are your enumeration tests: culture-based, quantitative, expressed in colony-forming units per gram (CFU/g). The question <61> answers is: how many microorganisms are present?

USP <62> — Microbiological Examination of Nonsterile Products: Tests for Specified Microorganisms — is a qualitative screen. It covers detection methods for specific pathogens and indicator organisms: Salmonella spp., Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, bile-tolerant gram-negative bacteria, Clostridia, and Candida albicans. The question <62> answers is: is this specific dangerous organism present at all?

One chapter counts. The other detects. Both are expected under 21 CFR Part 111 — the cGMP regulations governing dietary supplement manufacturing — and they answer fundamentally different compliance questions.

The Acceptance Criteria: Where the Confusion Lives

The methods in <61> and <62> are only half the picture. What your results are measured against comes from a separate set of USP general chapters: <2021> for pharmaceutical products and <2022> for nutritional and dietary supplements specifically.

USP <2022> is the current reference for dietary supplement acceptance criteria, and it organizes limits by product type and route of administration. For most finished oral supplement forms — capsules, tablets, powders intended for reconstitution — the representative limits are:

• TAMC: not more than 10³ CFU/g (1,000 CFU/g)
• TYMC: not more than 10² CFU/g (100 CFU/g)
• Bile-tolerant gram-negative bacteria: not more than 10² CFU/g
• E. coli: absent in 1 g
• Salmonella spp.: absent in 10 g

Botanical raw materials carry substantially higher allowable TAMC limits — up to 10⁷ CFU/g for unprocessed dried plant material — which reflects the microbial load that naturally comes with materials harvested from soil environments. What matters practically is that your raw material specifications and your finished product specifications are not interchangeable, and your contract lab needs to know which category applies to what you’re submitting.

Here’s the real-world problem: when brands submit samples without specifying the intended product category or referencing the correct acceptance criteria, labs may run the tests and report numbers without flagging whether those numbers represent a pass or a fail. Reporting a TAMC of 5,000 CFU/g is useful. Knowing whether that’s a compliance failure for your specific dosage form is what makes the COA actionable.

Incubation Conditions — The Detail That Changes Results

The methods in <61> specify precise incubation parameters, and deviations here meaningfully affect count outcomes. Bacterial enumeration (TAMC) requires incubation at 30–35°C for not less than 3 days. Fungal enumeration (TYMC) runs at 20–25°C for not less than 5 days.

These aren’t arbitrary numbers. Aerobic mesophiles — the bacterial population TAMC captures — grow optimally in that 30–35°C window. Yeasts and molds are slower growers that require the cooler, longer incubation window to develop visible colonies. Running the TYMC at bacterial incubation temperatures, or pulling plates early, produces artificially low counts.

When clients bring us COAs from other labs for a second opinion — which happens more than you’d think before an FDA inspection — one of the first things we check is whether incubation conditions and hold times are documented. Under ISO 17025, labs are required to maintain and record these parameters for every analytical run. That documentation trail is what regulators and auditors want to see: not just the final number, but the methodology that produced it.

The Specified Organism Panel You Can’t Skip

The organisms tested under <62> represent real public health hazards. Salmonella in a probiotic supplement. S. aureus in a protein powder. P. aeruginosa in a botanical extract marketed for immune support. These aren’t hypothetical scenarios — each has driven product recalls in the past several years.

And yet, because the <61> enumeration panel is sometimes faster or less expensive, brands occasionally omit the <62> panel — particularly for products where enumeration results historically come in low. That’s the wrong logic, and it misunderstands what low counts tell you.

A TAMC of 200 CFU/g does not confirm that Salmonella is absent. Pathogens can be present at levels well below enumeration detection thresholds while still representing a serious contamination event. The absence/presence methodology in <62> is specifically designed to detect low-level contamination across a larger analytical sample — typically 10 g for Salmonella — precisely because enumeration would miss it.

Under 21 CFR 111.70(b), manufacturers must establish finished product specifications that address microbial contamination. Under 21 CFR 111.75, they must verify those specifications are met before releasing product. FDA’s interpretation is consistent: specified organism testing is an expected element of that verification, not an optional line item on the testing budget.

What a Microbial Failure Actually Means — and What to Do Next

Microbial OOS results in dietary supplements split into two distinct situations, and the appropriate response to each is different.

Enumeration exceedance (TAMC or TYMC too high): This typically points upstream — inadequate cleaning and sanitation of manufacturing equipment, cross-contamination from high-load raw materials, moisture ingress during filling or packaging, or an environmental monitoring program that isn’t catching harborage points. The investigation needs to follow root cause, not the number. Submitting a retest request hoping for a lower count due to sample variability is not a corrective action, and any FDA investigator reviewing your batch records will recognize that immediately.

Specified organism detection (positive Salmonella, E. coli, etc.): This is a potential recall event. A dietary supplement testing positive for Salmonella is adulterated under section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act. The response involves immediate lot quarantine, written notification through your quality system, root cause investigation, and — depending on distribution scope — proactive communication with FDA. There is no “retest and see” protocol that is defensible here.

In both scenarios, your batch disposition record needs to document what was observed, what was investigated, and the data-supported rationale for the final lot decision. That documentation is the tangible evidence of your cGMP compliance program, and it’s what protects you when regulators ask why a batch was released or destroyed.

Choosing the Right Lab for USP Microbial Testing

Not every lab offering “microbial testing” is running the full panel under validated USP methods with documented incubation records. When you’re evaluating a contract lab, ask these specific questions before you submit your first sample:

1. Are your microbial enumeration methods validated to USP <61>?
2. Do you run specified organism testing per <62>, or an equivalent method (ISO 11133, AOAC)?
3. Are you ISO 17025 accredited for microbiological testing, and what does your scope of accreditation cover?
4. Does your COA document incubation conditions, hold times, and method references?
5. What’s your typical turnaround for the full enumeration plus specified organism panel?

The method reference matters. A lab running an AOAC-validated method that is functionally equivalent to USP <62> is generally acceptable — but you should know exactly which method is in use and be able to justify that choice to an FDA investigator if asked. “The lab ran something” is not a cGMP-compliant answer.

Our microbiology team at Qalitex runs USP <61> and <62> methods under ISO 17025 accreditation from A2LA, which means every method has been validated, every analyst has been assessed for competency on that procedure, and results are reviewed against documented acceptance criteria before any COA is issued. That accreditation scope — including specific microbiological methods — is listed on our public A2LA certificate, which is worth verifying for any testing partner you’re considering.

Before You Release Your Next Batch

Pull the last microbiology COA your lab issued for a finished product and check for three things: TAMC and TYMC results with documented acceptance criteria from USP <2022>, a full specified organism panel with method references for each pathogen, and incubation conditions on record or available on request. If any of those elements are missing, that conversation needs to happen with your testing partner before the next batch ships — not after an FDA investigator asks the same question.

---

Written by Nour Abochama, Vice President of Operations, Qalitex Laboratories. Learn more about our team

Talk to our team about your testing needs. Contact us

Related from our network

• Raw Material Microbial Testing and Supplier Qualification — Ayah Labs covers incoming ingredient testing protocols and COA verification for B2B raw material suppliers.
• GMP Compliance and FDA Audit Readiness for Dietary Supplement Manufacturers — Aurora TIC provides regulatory consulting on 21 CFR Part 111, quality systems, and FDA inspection preparedness.
• Dietary Supplement Testing for the Canadian Market — Androxa supports NHP and supplement brands navigating Health Canada’s microbial requirements alongside US standards.